Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Allogeneic transplantation in primary refractory AML.

Literature DB >> 28436972

Allogeneic transplantation in primary refractory AML.

P Ferguson¹, C Craddock^1,2.

Abstract

Entities: Disease

Mesh：

Year: 2017 PMID： 28436972 DOI： 10.1038/bmt.2017.61

Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483

× No keyword cloud information.

19 in total

1. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Authors: Andrew M Brunner; Shuli Li; Amir T Fathi; Martha Wadleigh; Vincent T Ho; Kerry Collier; Christine Connolly; Karen K Ballen; Corey S Cutler; Bimalangshu R Dey; Areej El-Jawahri; Sarah Nikiforow; Steven L McAfee; John Koreth; Daniel J Deangelo; Edwin P Alyea; Joseph H Antin; Thomas R Spitzer; Richard M Stone; Robert J Soiffer; Yi-Bin Chen
Journal: Br J Haematol Date: 2016-07-19 Impact factor: 6.998

2. Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors: Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245

3. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Authors: Paul Ferguson; Robert K Hills; Angela Grech; Sophie Betteridge; Lars Kjeldsen; Michael Dennis; Paresh Vyas; Anthony H Goldstone; Donald Milligan; Richard E Clark; Nigel H Russell; Charles Craddock
Journal: Haematologica Date: 2016-08-18 Impact factor: 9.941

4. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.

Authors: Marlise R Luskin; Martin Carroll; David Lieberman; Jennifer J D Morrissette; Jianhua Zhao; Lisa Crisalli; David B Roth; Selina M Luger; David L Porter; Ran Reshef
Journal: Biol Blood Marrow Transplant Date: 2016-07-28 Impact factor: 5.742

Review 5. Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.

Authors: Farhad Ravandi
Journal: Br J Haematol Date: 2011-09-13 Impact factor: 6.998

6. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.

Authors: Maria Liga; Evangelia Triantafyllou; Maria Tiniakou; Polyxeni Lambropoulou; Marina Karakantza; Nicholas C Zoumbos; Alexandros Spyridonidis
Journal: Biol Blood Marrow Transplant Date: 2012-08-04 Impact factor: 5.742

7. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.

Authors: Marjan Cruijsen; Willemijn Hobo; Walter J F M van der Velden; Manita E J Bremmers; Rob Woestenenk; Brigitte Bär; J H Frederik Falkenburg; Michel Kester; Nicolaas P M Schaap; Joop Jansen; Nicole N M Blijlevens; Harry Dolstra; Gerwin Huls
Journal: Biol Blood Marrow Transplant Date: 2016-02-06 Impact factor: 5.742

8. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.

Authors: C Craddock; M Labopin; S Pillai; J Finke; D Bunjes; H Greinix; G Ehninger; N-K Steckel; A R Zander; R Schwerdtfeger; S Buchholz; H-J Kolb; L Volin; A Fauser; E Polge; C Schmid; M Mohty; V Rocha
Journal: Leukemia Date: 2011-02-22 Impact factor: 11.528

9. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

Authors: Victoria T Potter; Pramila Krishnamurthy; Linda D Barber; Ziyi Lim; Michelle Kenyon; Robin M Ireland; Hugues de Lavallade; Abdel Dhouri; Judith C W Marsh; Robert Marcus; Stephen Devereux; Aloysius Ho; Antonio Pagliuca; Ghulam J Mufti
Journal: Biol Blood Marrow Transplant Date: 2013-11-08 Impact factor: 5.742

10. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors: Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal: Biol Blood Marrow Transplant Date: 2015-09-09 Impact factor: 5.742

2 in total

1. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.

Authors: K H Begna; J Kittur; N Gangat; H Alkhateeb; M S Patnaik; A Al-Kali; M A Elliott; W J Hogan; M R Litzow; A Pardanani; C A Hanson; R P Ketterling; A Tefferi
Journal: Blood Cancer J Date: 2022-01-17 Impact factor: 11.037

Review 2. Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors: Christian M Schürch
Journal: Front Oncol Date: 2018-05-18 Impact factor: 6.244

2 in total